Abstract #2209
MRS of Basal-Ganglia in Parkinsons Disease Reveals Higher GABA Levels
Shalmali Dharmadhikari 1,2 , Ruoyun Ma 1,2 , Chien- Lin Yeh 1,2 , Sandy Snyder 1 , S E Zauber 3 , and Ulrike Dydak 1,2
1
School of Health Sciences, Purdue
University, W Lafayette, IN, United States,
2
Department
of Radiology and Imaging Sciences, Indiana University
School of Medicine, Indianapolis, IN, United States,
3
Department
of Neurology, Indiana University School of Medicine,
Indianapolis, IN, United States
Gamma-aminobutyric acid (GABA) is an important
inhibitory neurotransmitter of the basal ganglia, which
is hypothesized to be altered in Parkinsons disease
(PD). Our aim was to evaluate the use of GABA MRS for
understanding these alterations and their relation to
disease severity, while reducing influence of PD
medicines. GABA MRS in PD patients, who were temporarily
withheld medication, revealed elevated GABA levels in
the thalamus, which were also associated with disease
severity as measured clinically by motor scores. Thus
GABA MRS confirms the role of GABA in PD and has a
potential to be used a non-invasive biomarker of PD.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
